The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

A Study of Olaparib and Cediranib in Ovarian Cancer

Christina M. Annunziata, MD, PhD
Published Online:8:57 PM, Wed March 22, 2017

Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.